Investigate the adhesion molecules that control the progression of endometriosis.
Project/Area Number |
25462592
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Obstetrics and gynecology
|
Research Institution | Osaka University |
Principal Investigator |
Hashimoto Kae 大阪大学, 医学(系)研究科(研究院), 助教 (90612078)
|
Co-Investigator(Kenkyū-buntansha) |
Sawada Kenjiro 大阪大学, 医学系研究科, 講師 (00452392)
Mabuchi Seiji 大阪大学, 医学系研究科, 助教 (00452441)
Isobe Aki 大阪大学, 医学系研究科, 助教 (60397619)
|
Project Period (FY) |
2013-04-01 – 2016-03-31
|
Project Status |
Completed (Fiscal Year 2015)
|
Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2015: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
Keywords | 子宮内膜症 / 接着因子 / 接着 |
Outline of Final Research Achievements |
iTRAQ-based proteomics demonstrated that VCAM-1 was one of the increased membrane proteins of endometrial stromal cell of ovarian endometrial cyst (eESC) in comparison of normal eutopic endometrial stromal cells. Immunohistochemistry of endometriotic cyst and normal uterus showed comparative result. At eESC, VCAM-1 was regulated by nuclear factor kappa B (NF-κB). Adhesion of endometrial cell to peritoneal wall is one of the favored mechanisms of arising endometriosis. VCAM-1 neutralizing antibody and IKK inhibitor, which inhibits NF-κB activation, decreased adhesive activity of eESC to human peritoneal mesothelial cells (HPMC). In conclusion, VCAM-1 is the novel therapeutic target of endometriosis, and VCAM-1 neutralizing antibody and IKK inhibitor is potent therapeutic drug of endometriosis.
|
Report
(3 results)
Research Products
(3 results)